At a glance
- Originator Pfizer
- Class Antibacterials; Macrolides
- Mechanism of Action Protein 50S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 23 Jun 2000 Pfizer has merged with Warner-Lambert
- 14 Oct 1998 New profile
- 14 Oct 1998 Preclinical development for Bacterial infections in USA (Unknown route)